These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38013668)

  • 21. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Paz-Ares LG; Pérol M; Ciuleanu TE; Kowalyszyn RD; Reck M; Lewanski CR; Syrigos K; Arrieta O; Prabhash K; Park K; Pikiel J; Göksel T; Lee P; Zimmermann A; Carter GC; Alexandris E; Garon EB
    Lung Cancer; 2017 Oct; 112():126-133. PubMed ID: 29191585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
    Tanizaki S; Matsumoto K; Tamiya A; Taniguchi Y; Matsuda Y; Uchida J; Ueno K; Kawachi H; Tamiya M; Yanase T; Suzuki H; Okishio K
    Eur J Clin Pharmacol; 2023 Apr; 79(4):503-511. PubMed ID: 36773042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JC; Bajars M; Ruisi M; Manitz J; Barlesi F
    Lung Cancer; 2021 Apr; 154():92-98. PubMed ID: 33636453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Reck M; Paz-Ares L; Bidoli P; Cappuzzo F; Dakhil S; Moro-Sibilot D; Borghaei H; Johnson M; Jotte R; Pennell NA; Shepherd FA; Tsao A; Thomas M; Carter GC; Chan-Diehl F; Alexandris E; Lee P; Zimmermann A; Sashegyi A; Pérol M
    Lung Cancer; 2017 Oct; 112():181-187. PubMed ID: 29191593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
    Grohé C; Blau W; Gleiber W; Haas S; Hammerschmidt S; Krüger S; Müller-Huesmann H; Schulze M; Wehler T; Atz J; Kaiser R
    Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):459-468. PubMed ID: 35012901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
    Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
    Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
    Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Nishioka N; Katayama Y; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Target Oncol; 2023 Nov; 18(6):915-925. PubMed ID: 37902896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
    Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M
    Clin Lung Cancer; 2012 Nov; 13(6):505-9. PubMed ID: 22853980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
    Qin K; Wang K; Li S; Hong L; Padmakumar P; Waree R; Hubert SM; Le X; Vokes N; Rai K; Vaporciyan A; Gibbons DL; Heymach JV; Lee JJ; Woodman SE; Chung C; Jaffray DA; Altan M; Lou Y; Zhang J
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
    Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G
    BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
    Brueckl WM; Reck M; Rittmeyer A; Kollmeier J; Wesseler C; Wiest GH; Christopoulos P; Tufman A; Hoffknecht P; Ulm B; Reich F; Ficker JH; Laack E
    Clin Med Insights Oncol; 2020; 14():1179554920951358. PubMed ID: 32884390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
    Kawachi H; Tamiya M; Matsumoto K; Tamiya A; Yanase T; Tanizaki S; Kumagai T
    Invest New Drugs; 2022 Jun; 40(3):634-642. PubMed ID: 35024985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
    Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
    Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
    Ramalingam SS; Pérol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N; Dakhil S; Lee P; Zimmerman A; Sashegyi A; Alexandris E; Carter GC; Winfree KB; Garon EB
    Clin Lung Cancer; 2018 May; 19(3):270-279.e3. PubMed ID: 29373274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
    Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
    Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
    Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study.
    Matsumoto K; Tamiya A; Inagaki Y; Taniguchi Y; Matsuda Y; Kawachi H; Tamiya M; Tanizaki S; Uchida J; Ueno K; Yanase T; Suzuki H; Atagi S
    J Geriatr Oncol; 2022 Mar; 13(2):207-213. PubMed ID: 34602370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.